Entering text into the input field will update the search result below

Senators urge CMS not to restrict coverage of Biogen Alzheimer's drug Aduhelm

Mar. 03, 2022 10:29 AM ETBiogen Inc. (BIIB)By: Jonathan Block, SA News Editor4 Comments

Senate Judiciary Committee Scrambles After Accusations Against Judge Kavanaugh

Win McNamee/Getty Images News

  • Sens. Susan Collins (R-Maine) and Shelley Moore Capito (R-W.V.) are asking the Centers for Medicare and Medicaid Services ("CMS") to not restrict patient access to Biogen's (BIIB +1.9%) Alzheimer's treatment Aduhelm (aducanumab).
  • In January, CMS issued

Recommended For You

Comments (4)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

Pretty sure Medicare won’t listen to them also by chance if Medicare approved It no doctors will prescribe it . It’s a dead meat now
smikhail profile picture
Politicians opining on the efficacy of a drug's merit is asinine. Call me cynical, but I would not be shocked if the basis of their concern is they are long BIIB.
@smikhail no doubt. They are clueless, and are only concerned about their own pockets. I’d be surprised if that wasn’t the case.
03 Mar. 2022
Hmmm I wonder who pays Jonathon Block? What a mystery this is.

About BIIB

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Biogen Inc.
Moderna, Inc.
argenx SE
Seagen Inc.
BioNTech SE
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.